Internal Medicine Department
Hematology Division

Maurizio Zangari, MD

Email:    maurizio.zangari@hsc.utah.edu

Education:

1974 – 1980    M.D., University of Padua, Padua, Italy

1968 – 1974    B.A., Enrico Fermi Institute of Padua, Padua, Italy

Training:

1993 – 1995    Fellow in Bone Marrow Transplantation, Mount Sinai Hospital, New York, New York

1991 – 1993    Fellow in Hematology, Mount Sinai Hospital, New York, New York

1988 – 1990    Resident in Internal Medicine, Wykoff Heights Medical Center, Brooklyn, New York

1981 – 1984    Fellow in ENT, University of Padua, Padua, Italy

1979 – 1981    Internship in Oncology and ENT, Ospedale Civile de Camposampiero, Mirano, Italy

Research Interests:

Hypercoagulability in cancer patients
Phase I studies of novel anticancer agents

Recent Bibliography

  1. Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E, Waldron J, Pineda-Roman M, Thertulien R, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Crowley J, Sawyer J. (2008). Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989. Blood, 111(1):94-100.
  2. Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy J, Epstein J, Crowley J. (2007). The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol, 20(4):761-81.
  3. Haessler J, Shaughnessy JD Jr, Zhan F, Crowley J, Epstein J, van Rhee F, Anaissie E, Pineda-Roman M, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Tricot G, Barlogie B. (2007). Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res, 13(23):7073-9.
  4. Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, Munshi NC. (2007). A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.Clin Adv Hematol Oncol, 5(10 Suppl 15):7-19, quiz 21-2.
  5. Zangari M, Barlogie B, Cavallo F, Bolejack V, Fink L, Tricot G. (2007). Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagul Fibrinolysis, 18(7):595-8.
  6. Camozzi V, Luisetto G, Zangari M, Lumachi F. (2007). Quantitative Ultrasound Technology in Evaluating Bone Status and Osteoporosis in Patients with Cushing's Syndrome. Ann N Y Acad Sci, 1117:352-6.
  7. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD Jr. (2007). Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol, 138(2):176-85.
  8. Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G. (2007). Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol, 82(9):831-3.
  9. Zangari M, Elice F, Fink L, Tricot G. (2007). Hemostatic dysfunction in paraproteinemias and amyloidosis. Semin Thromb Hemost, 33(4):339-49.
  10. Shaughnessy JD Jr, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B. (2007). Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol, 137(6):530-6.
  11. Gokden N, Zangari M, Elici F, Barlogie B, Kumar J. (2007). Potential effect of zoledronate therapy in heavy proteinuria. Clin Nephrol, 67(4):263-5.
  12. Camozzi V, De Terlizzi F, Zangari M, Luisetto G. (2007). Quantitative bone ultrasound at phalanges and calcaneus in osteoporotic postmenopausal women: influence of age and measurement site. Ultrasound Med Biol, 33(7):1039-45.
  13. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD Jr, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B. (2007). High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood, 110(3):827-32.
  14. Talamo G, Cavallo F, Zangari M, Barlogie B, Lee CK, Pineda-Roman M, Kiwan E, Krishna S, Tricot G. (2007). Hyperammonemia and encephalopathy in patients with multiple myeloma. Am J Hematol, 82(5):414-5.
  15. Zangari M, Elice F, Fink L, Tricot G. (2007). Thrombosis in multiple myeloma. Expert Rev Anticancer Ther, 7(3):307-15.
  16. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ. (2007). Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol, 25(9):1121-8.
  17. Pineda-Roman M, Bolejack V, Arzoumanian V, Anaissie E, van Rhee F, Zangari M, Walker R, Hollmig K, Shaughnessy JD Jr, Epstein J, Krishna S, Crowley J, Barlogie B. (2007). Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol, 136(3):393-9.
  18. Zangari M, Cavallo F, Tricot G. (2006). Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma. Curr Pharm Biotechnol, 7(6):449-53.